Skip to Content

Tag: BioScrip


News

In brief: Hillrom to buy Breathe Technologies; Option Care, BioScrip complete merger

August 9, 2019HME News Staff

CHICAGO - Hillrom has entered into a definitive agreement to buy Breathe Technologies, an Irvine, Calif.-based manufacturer of patented, wearable non-invasive ventilators, for $130 million.“The acquisition provides an exciting growth platform that utilizes our direct Respiratory Care commercial channel and business model,” said John Groetelaars, president and CEO of Hillrom. “This transaction represents another example of our plan to strategically deploy capital with a disciplined...

BioScrip, Breathe Technologies, Hillrom, Home Infusion, M&A, Merger, Option Care, Vents


Read Full Articlered right arrow icon

Also Noted

Option Care, BioScrip complete merger

August 8, 2019HME News Staff

BANNOCKBURN, Ill., and DENVER - Option Care Enterprises and BioScrip have completed their merger, forming a newly combined company named Option Care Health. The deal has met closing conditions, including approval by BioScrip shareholders and the receipt of all necessary regulatory approvals. “Today marks the beginning of an exciting new chapter as we unite two strong organizations with proud histories as market leaders,” said John Rademacher, CEO of Option Care Health. Option Care Health's...

BioScrip, Home Infusion, M&A, Option Care


Read Full Articlered right arrow icon

Also Noted

BioScrip, Option Care merger approved

August 2, 2019HME News Staff

DENVER - BioScrip stockholders today approved the merger with Option Care. The merger is expected to close on or about Aug. 6. BioScrip and OptionCare announced their merger in March. John Rademacher will be CEO of the combined company and BioScrip President and CEO Dan Greenleaf will be special adviser to the company's board chairman, Henry Kraemer.

BioScrip, Home Infusion, Option Care


News

In brief: BioScrip, Option Care report earnings, NSM makes acquisition

August 2, 2019HME News Staff

DENVER - BioScrip and Option Care both report increased revenues for the second quarter of 2019.BioScrip reported net revenues of $191.5 million for the second quarter 2019, an 8.9% increase compared to $175.8 million during the same period last year. Gross revenue was $196.8 million, an increase of 13.1%. Adjusted EBITDA was $15.5 million, up 35.4%.On Friday, BioScrip announced that stockholders approved its planned merger with Option Care, expected to close on or about Aug. 6. The merger was announced...

BioScrip, Medtrade, Option Care, Responsive Respiratory


Read Full Articlered right arrow icon

Specialty Providers

BioScrip, Option Care report earnings

July 31, 2019HME News Staff

DENVER - Ahead of their planned merger, BioScrip and Option Care both reported increased revenues for the second quarter of 2019. BioScrip reported net revenues of $191.5 million for the second quarter 2019, an 8.9% increase compared to $175.8 million during the same period last year. Gross revenue was $196.8 million, an increase of 13.1%. Adjusted EBITDA was $15.5 million, up 35.4%. “This is the fifth consecutive quarter of sequential, comparable gross revenue growth for BioScrip, and...

BioScrip, Home Infusion, Option Care


Read Full Articlered right arrow icon

Also Noted

BioScrip execs will continue at combined company

June 13, 2019HME News Staff

DENVER - Key members of BioScrip's leadership team will continue in executive roles with the combined company following the close of its pending merger with Option Care Enterprises. Dan Greenleaf, president and CEO of BioScrip, will become special advisor to the newly combined company's board chairman, Harry Kraemer, and CEO John Rademacher. Greenleaf will provide strategic and operational counsel to ensure a smooth transition, optimize the integration of both companies and drive long-term opportunities....

BioScrip, Home Infusion, M&A, Merger, Option Care


Read Full Articlered right arrow icon

News

In brief: KCI sells to 3M, senators introduce accessories bill

May 3, 2019HME News Staff

SAN ANTONIO and NEW YORK - A consortium of funds led by Apax Partners has entered into a definitive agreement to sell Acelity and its KCI subsidiaries worldwide to 3M for about $6.725 billion.KCI markets a broad range of negative pressure wound therapy, specialty surgical and advanced wound care dress products in about 90 countries.“Today, KCI embarks upon a new era,” said R. Andrew Eckert, CEO of Acelity. “Backed by the resources and expertise of 3M, KCI will be able to offer clinicians...

3B Medical, aahomecare, Acelity, BioScrip, CRT Accessories


Read Full Articlered right arrow icon

Also Noted

BioScrip reports revenue growth

May 2, 2019HME News Staff

DENVER - BioScrip reported revenues of $179 million for the first quarter of 2019, an increase of 6.2% over the first quarter of 2018. Net loss from continuing operations was $10.3 million vs. $13 million. Adjusted EBITDA was $7.1 million, up 25.6%, despite a bad debt expense increase of $4.5 million. “This is the third consecutive quarter of comparable net revenue growth for BioScrip, and we are confident this trend will continue,” said Daniel Greenleaf, president and CEO. BioScrip's...

BioScrip, Home Infusion, Option Care


Read Full Articlered right arrow icon

Specialty Providers

Q&A: Option Care's John Rademacher

April 29, 2019Theresa Flaherty, Managing Editor

When the ink dries on the planned merger of two of the country's leading home infusion services providers, it will form an organization that is deeply committed to patient care, says John Rademacher, CEO of the combined company of Option Care and BioScrip.“At the center of both organizations is deep clinical expertise and a passion to deliver extraordinary care,” he told HME News in an email. “Together, we will form an organization that will create a rich environment and a destination...

BioScrip, Home Infusion, John Rademacher, Option Care


Read Full Articlered right arrow icon

Specialty Providers

Option Care positions itself as 'partner of choice'

March 22, 2019Theresa Flaherty, Managing Editor

DENVER, Colo., and BANNOCKBURN, Ill. - Option Care CEO John Rademacher says its merger with BioScrip will create a “powerful, independent platform” in the growing $100 million infusion market.“Combining each company's unique assets and leading product portfolios will create a powerful, independent platform that will enable delivery of high-quality, cost effective solutions to providers across the country and help facilitate the introduction of innovative new therapies to the market...

BioScrip, Home Infusion, Option Care


Read Full Articlered right arrow icon